VIRX
Income statement / Annual
Last year (2023), Viracta Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Viracta Therapeutics, Inc.'s net income was -$51.06 M.
See Viracta Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$120,000.00
|
$2.07 M
|
$237,000.00
|
$669,000.00
|
$2.54 M
|
$3.06 M
|
$5.73 M
|
| Cost of Revenue |
$492,000.00 |
$210,000.00 |
$178,000.00 |
$32,000.00 |
$0.00 |
-$902,745.00 |
$9,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$492,000.00 |
-$210,000.00 |
-$178,000.00 |
$88,000.00 |
$2.07 M |
$1.14 M |
$660,000.00 |
$2.54 M |
$3.06 M |
$5.73 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0.73 |
1 |
4.81 |
0.99 |
1 |
1 |
1 |
| Research and Development
Expenses |
$33.37 M
|
$26.26 M
|
$23.86 M
|
$13.47 M
|
$15.41 M
|
$14.62 M
|
$21.54 M
|
$22.88 M
|
$23.70 M
|
$27.67 M
|
| General & Administrative
Expenses |
$17.32 M
|
$24.33 M
|
$15.44 M
|
$5.35 M
|
$3.19 M
|
$2.14 M
|
$13.55 M
|
$16.12 M
|
$18.66 M
|
$23.11 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.95 M
|
$9.18 M
|
-$9,000.00
|
-$11,000.00
|
-$27,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$17.32 M
|
$24.33 M
|
$15.44 M
|
$5.35 M
|
$9.95 M
|
$11.32 M
|
$13.54 M
|
$16.10 M
|
$18.64 M
|
$23.11 M
|
| Other Expenses |
$0.00 |
$1.39 M |
-$13.50 M |
-$34,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$50.69 M |
$50.59 M |
$25.80 M |
$18.82 M |
$25.36 M |
$25.94 M |
$35.08 M |
$38.99 M |
$42.34 M |
$50.78 M |
| Cost And Expenses |
$50.69 M |
$50.59 M |
$25.80 M |
$18.82 M |
$25.36 M |
$25.95 M |
$35.09 M |
$39.00 M |
$42.36 M |
$50.78 M |
| Interest Income |
$3.35 M |
$1.17 M |
$38,000.00 |
$48,000.00 |
$472,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$3.70 M |
$577,000.00 |
$491,000.00 |
$216,000.00 |
$514,000.00 |
$1.15 M |
$1.40 M |
$1.72 M |
$939,000.00 |
$1.72 M |
| Depreciation &
Amortization |
$492,000.00
|
$210,000.00
|
$178,000.00
|
$32,000.00
|
$3,135.00
|
$9,000.00
|
$9,000.00
|
$11,000.00
|
$27,000.00
|
$29,000.00
|
| EBITDA |
-$46.86 M
|
-$48.41 M
|
-$114.09 M
|
-$18.77 M
|
-$22.82 M
|
-$25.45 M
|
-$34.05 M
|
-$36.29 M
|
-$35.71 M
|
-$41.25 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-156.41 |
-5.82 |
-108.44 |
-51.43 |
-14.37 |
-12.83 |
-7.19 |
| Operating Income Ratio
|
0
|
0
|
0
|
-156.79
|
-11.23
|
-108.48
|
-51.45
|
-14.38
|
-12.84
|
-7.2
|
| Total Other
Income/Expenses Net |
-$365,000.00
|
$1.39 M
|
-$75.46 M
|
-$202,000.00
|
-$42,000.00
|
-$905,000.00
|
-$1.04 M
|
-$1.56 M
|
$2.63 M
|
$2.04 M
|
| Income Before Tax |
-$51.06 M |
-$49.20 M |
-$114.76 M |
-$19.02 M |
-$23.33 M |
-$26.62 M |
-$35.46 M |
-$38.02 M |
-$36.68 M |
-$43.00 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-158.48
|
-11.25
|
-112.3
|
-53
|
-14.99
|
-11.98
|
-7.5
|
| Income Tax Expense |
$0.00 |
$577,000.00 |
$88.30 M |
$182,000.00 |
$514,000.00 |
$1.15 M |
$1.40 M |
$1.72 M |
$939,000.00 |
$1.72 M |
| Net Income |
-$51.06 M |
-$49.77 M |
-$203.06 M |
-$19.20 M |
-$23.33 M |
-$26.62 M |
-$35.46 M |
-$38.02 M |
-$36.68 M |
-$44.72 M |
| Net Income Ratio |
0 |
0 |
0 |
-159.99 |
-11.25 |
-112.3 |
-53 |
-14.99 |
-11.98 |
-7.8 |
| EPS |
-1.32 |
-1.32 |
-6.37 |
-206.93 |
-9.37 |
-26.18 |
-50.62 |
-84.83 |
-105.6 |
-44.68 |
| EPS Diluted |
-1.32 |
-1.32 |
-6.37 |
-206.93 |
-9.37 |
-26.18 |
-50.62 |
-84.83 |
-105.6 |
-43.62 |
| Weighted Average Shares
Out |
$38.62 M
|
$37.79 M
|
$31.87 M
|
$92,779.00
|
$2.49 M
|
$1.02 M
|
$700,457.00
|
$448,228.00
|
$347,299.00
|
$1.00 M
|
| Weighted Average Shares
Out Diluted |
$38.62 M
|
$37.79 M
|
$31.87 M
|
$92,779.00
|
$2.49 M
|
$1.02 M
|
$700,457.00
|
$448,228.00
|
$347,299.00
|
$1.03 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
